Vaccitech surges despite Morgan Stanley downgrade

seekingalpha2023-09-26

Vaccitech plc (NASDAQ:VACC) ADRs advanced on Monday on above-average volumes even as Morgan Stanley downgraded the U.K.-based developer of cellular immunotherapeutics to Equal Weight from Overweight. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2370129038?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185318210/image_185318210.jpg","is_english":true,"pubTime":"2023-09-26 03:34","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2370129038","market":"us","top_or_hot":-1,"title":"Vaccitech surges despite Morgan Stanley downgrade","media":"seekingalpha","content":"<div>\n<p>Vaccitech plc (NASDAQ:VACC) ADRs advanced on Monday on above-average volumes even as Morgan Stanley downgraded the U.K.-based developer of cellular immunotherapeutics to Equal Weight from Overweight. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4015180-vaccitech-stock-surges-despite-morgan-stanley-downgrade\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccitech surges despite Morgan Stanley downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccitech surges despite Morgan Stanley downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-26 03:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4015180-vaccitech-stock-surges-despite-morgan-stanley-downgrade><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccitech plc (NASDAQ:VACC) ADRs advanced on Monday on above-average volumes even as Morgan Stanley downgraded the U.K.-based developer of cellular immunotherapeutics to Equal Weight from Overweight. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4015180-vaccitech-stock-surges-despite-morgan-stanley-downgrade\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4504","symbol_name":"桥水持仓","start_time":0,"source_url":"https://seekingalpha.com/news/4015180-vaccitech-stock-surges-despite-morgan-stanley-downgrade","article_id":"2370129038","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185318210/image_185318210.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2370129038","pubTimestamp":1695670475,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Vaccitech plc  ADRs advanced on Monday on above-average volumes even as Morgan Stanley downgraded the U.K.-based developer of cellular immunotherapeutics to Equal Weight from Overweight. The microcap biotech doubled in value to reach the highest level in more than a year at the close of regular trading. ~34.5M of its ADRs were changing hands compared to the 65-day volume of ~13.5K.  Morgan Stanley Maxwell Skor’s bearish thesis mainly centers on VTP-300, Vaccitech’s  most advanced asset targeted at chronic hepatitis B infection . He cuts his probability of success for VTP-300, citing concerns about a combination approach to treat CHB and a requirement to reduce surface antigen levels  before the treatment. Skor argued that the requirement for low surface antigens and the unknowns of combining multiple approaches to treat HBV complicate VTP-300’s market entry and limit its total addressable market. While Morgan Stanley cut its price target to $3.25 from $14, Alliance Global Partners laun","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4504":"桥水持仓","BK4127":"投资银行业与经纪业","BK4539":"次新股","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","CHB":"Global X China Biotech Innovation ETF","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","MS":"摩根士丹利","BK4139":"生物科技","BK4581":"高盛持仓","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0106831901.USD":"贝莱德世界金融基金A2","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4588":"碎股","LU0971096721.USD":"富达环球金融服务 A","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H"},"translate_title":"尽管摩根士丹利评级下调，但Vaccitech股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VACC":1,"MS":1,"CHB":1},"content_text":"Vaccitech plc (NASDAQ:VACC) ADRs advanced on Monday on above-average volumes even as Morgan Stanley downgraded the U.K.-based developer of cellular immunotherapeutics to Equal Weight from Overweight. The microcap biotech doubled in value to reach the highest level in more than a year at the close of regular trading. ~34.5M of its ADRs were changing hands compared to the 65-day volume of ~13.5K.  Morgan Stanley Maxwell Skor’s bearish thesis mainly centers on VTP-300, Vaccitech’s (VACC) most advanced asset targeted at chronic hepatitis B infection (CHB). He cuts his probability of success for VTP-300, citing concerns about a combination approach to treat CHB and a requirement to reduce surface antigen levels (HBsAg) before the treatment. Skor argued that the requirement for low surface antigens and the unknowns of combining multiple approaches to treat HBV complicate VTP-300’s market entry and limit its total addressable market. While Morgan Stanley cut its price target to $3.25 from $14, Alliance Global Partners launched its coverage on VACC with a $12 per share target and a Buy recommendation.   More on Vaccitech  Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2370129038"}